Q-omics provides the consensus-scored CD1E profile across patient tissues and cancer cell-line models. CD1E expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CD1E is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CD1E RNA expression shows 17,882 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where CD1E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD1E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD1E survival associations across molecular data types. CD1E RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD1E RNA expression–survival associations across cancer types. High CD1E expression shows favorable associations in KIRC, HNSC, CESC, LUAD, SKCM and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CD1E RNA expression.
This table summarizes CD1E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD1E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD1E shows lower tumor expression in HNSC, LUSC, LUAD and KICH and higher tumor expression in THCA and BRCA. The HNSC box plot shows higher CD1E RNA expression in normal versus tumor tissue (log2 FC = −0.969, t-test p < 0.001).
This table shows molecular features associated with CD1E in patient tissues and cancer cell lines. In patient samples, CD1E shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CD1E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
